On this episode of The Climate Biotech Podcast, Paul Reginato is joined by Kiara Reyes Gamas, environmental synthetic biologist and non-resident postdoctoral scholar at Rice University's Baker Institute. Alongside her bench science, she has consistently engaged with the social and governance dimensions of synthetic biology, which shapes how she thinks about engineering microbes for environmental release.

Much of Kiara’s work has focused on horizontal gene transfer, the process by which microbes naturally swap DNA throughout the environment. It is how antibiotic resistance spreads, and it is one of the central reasons regulators worry about releasing engineered microbes. The problem is that we have very poor measurements of how often it actually happens in natural settings in complex communities, or which organisms participate.

Kiara’s research also suggests that the field's default toward biocontainment may be missing the point for environmental applications. A microbe engineered to clean up an oil spill has to interact with the environment to do its job. The more useful questions are about which genes are safe to introduce, how engineered organisms behave under selective pressure in microbial communties, how to integrate human communities into the governance of these technologies, and whether the regulatory scrutiny applied to recombinant DNA should extend to any non-native microbe being released.

Listen to learn how RNA-based barcoding extends the reach of horizontal gene transfer measurements across microbial species, what ecology has to teach synthetic biologists about environmental release, and why Kiara argues that community co-design is an engineering requirement rather than a regulatory checkbox.

Send us Fan Mail

On this episode of The Climate Biotech Podcast, Paul is joined by Eli Hornstein, founder and CEO of Elysia Bio, a company engineering feed crops to address methane emissions from livestock. Eli came to plant biotech through an unlikely path: undergraduate degrees in ecology and linguistics, conservation fieldwork across East Africa and South America, and a Fulbright Fellowship in Mongolia before a PhD in plant genetic engineering at NC State. That ecological background shapes how Eli thinks about intervention points in agriculture.

One of Eli’s core insights is that plant biotech has spent decades optimizing plants for the plant's sake while largely ignoring that those plants are actually for feeding animals. Enteric methane from ruminants is the single largest source of methane on Earth – larger than oil and gas – and most of those animals are on pasture with few practical options for emissions reduction.

Elysia's first trait encodes bromoform, a methane-inhibiting compound from red seaweed, directly into corn so farmers don't need to change feeding practices. The company has since expanded into pasture grasses and other crops to reach ruminants outside commodity feed systems. Their most ambitious project, the PlaMMO Project, engineers plants to express methane monooxygenase (MMO), the enzyme methanotrophs use to oxidize methane, potentially enabling crops to pull methane directly from the atmosphere. Elysia is currently running analytical chemistry on their first MMO-expressing plant candidates.

Listen to learn about the community of researchers working to de-risk heterologous MMO expression, why plant synthetic biology is underrated relative to microbial systems, and why Eli thinks ecological thinking is one of the most undervalued skills in biotech. Plus, learn how a photosynthesizing sea slug inspired a company name.

Send us Fan Mail

In Dan Goodwin’s final episode as host, The Climate Biotech Podcast reflects on over 30 episodes of conversations with scientists, entrepreneurs, and builders at the frontier of climate biotechnology, and marks the official handover of the podcast to Homeworld Collective's new Executive Director and co-founder, Paul Reginato.

Dan and Paul trace their partnership back to MIT, where they were both developing first-of-kind spatial genomics technologies in Ed Boyden and George Church's labs. What started as a shared drive to work on climate change grew into organic community building, and eventually into Homeworld Collective, an organization designed to connect climate biotech practitioners with high-leverage problems, collaborators, and funding.

The episode distills wisdom from the podcast's guests so far. When asked what shaped them as thinkers, guests overwhelmingly cited science fiction and art over technical papers. On mentor advice, the theme was self-advocacy: pick hard problems, learn to communicate your work, and trust your own intuition. And when asked where a magic wand of climate biotech should point, answers ranged from better field measurements for methane to the largely untapped interface between geology and biology.

At the end of the episode, Paul shares his vision for Homeworld's phase two: refinement and scaling of Homeworld’s methods through more community convenings, a new ambassador program, faster production of problem statements, and more focused grantmaking designed to nucleate productive research communities in underserved, high-impact problem spaces. Dan reflects on his framework for choosing what comes next and highlights the underappreciated connection between environmental pollutants and the 70-80% of human disease that remains sporadic and unexplained.

Listen for the best career advice for early-career scientists, like "nail your projects, don't pick your track,” what a tadpole losing its tail teaches us about growth, and why building friendships across disciplinary boundaries can unlock your own potential to impact some of the most important problems of our time.

Send us Fan Mail

On the most recent episode of the Climate Biotech Podcast, we are joined by Ginger Krieg Dosier, an architect-turned-biotech entrepreneur who created biocement at Biomason and is now building BIOME Consortia to accelerate biology's transition from thousands to billions of applications. Ginger's journey from NASA kid in Alabama to founding one of climate biotech's earliest companies reveals how architectural thinking translates surprisingly well to biological innovation.

Ginger’s approach at Biomasontackled concrete, the second most consumed substance on Earth after water. By using microbes to precipitate calcium carbonate at ambient temperature instead of firing kilns at 1500°C, they cut both emissions and energy usage dramatically.

The pivot to BIOME emerged from a startling statistic: with an estimated one trillion microbial species on Earth and only 0.001% discovered, Ginger saw that the strain bank they'd built for biocement applications represented something far bigger. Today, fewer than 800 strains power all commercial applications - she believes we need billions by 2050.

BIOME’s two flagship initiatives address this gap. Atlas creates a digital microbial commons focused on access and interpretability, gamifying discovery and translation to engage more tinkerers. Arc tackles preservation, particularly of threatened environments like glaciers that lose tens of quadrillions of microbes to sea annually, while moving beyond minus-80 storage limitations.

Listen to learn why consortia-based biology may solve the scaling economics that sank many biomanufacturing companies, how visualization of the invisible microbiome could transform public engagement, and why the "age of complexity" might finally deliver on the 1999 prediction that the 21st century would be biology's era.

Send us Fan Mail

In this special episode, we sit down with Shuguang Zhang, Head of the Laboratory of Molecular Architecture in the MIT Media Lab and a mentor to countless biotech explorers. His personal story has at least one literal "1 in 100 Million" moment and demonstrates the power of curiosity, kindness, and always asking questions.

We trace how Shuguang's stubbornness to pursue questions long after others give up has taken him around the world and reshaped biology. "Why is some DNA left-handed?" is a question he couldn't stop asking as a young man in China. It led him to work with one of his heroes, Alexander Rich at MIT, where he discovered zoutin (from the Chinese word for left, 左, zuo), the critical protein for mysterious Z-DNA. When he purified this new protein, he became fascinated by how it self-assembled into structures visible to the naked eye—a discovery that became PuraMatrix, now used in wound healing worldwide, and sparked generations of curiosity about self-assembling peptides.

Similarly, wondering why there are both hydrophobic and hydrophilic alpha helices led to the QTY code: a beautifully simple method to convert any membrane protein into a water-soluble form. By swapping hydrophobic residues for polar look-alikes (Q, T, and Y) without breaking geometry, this unlocks dense high-signal sensors, "molecular trap" therapeutics targeting cancer metastasis, and a fresh way to treat receptors as modular parts rather than fragile mysteries.

The pattern repeats with S-layer proteins: nature's two-dimensional crystalline lattices that orient engineered receptors 100% upright at nanometer precision. Combined with QTY-solubilized proteins, these create clean bioelectronic interfaces, ultrasensitive arrays, and new possibilities for separations and chemical monitoring.

We widen the lens to climate: industrial-scale kelp systems for carbon capture and feed, biotech routes for ocean-based materials, and practical paths to planetary solutions that borrow from biology's atomic precision and self-assembly. Kelp's exceptional photosynthetic efficiency and rapid growth make it a promising system that biotechnology could enhance through genetic engineering.

Threaded through it all are lessons from mentors like Francis Crick ("ask big questions, you get bigger answers") and Alexander Rich ("it's equally important to know what not to do"). As Shuguang puts it: "In doing science, we see a lot of things, but don't observe. To observe is to pay attention." We also talk frankly about funding setbacks, debt, persistence, and the role of AI: powerful at pattern completion, weak at original curiosity.

If you care about proteins, materials, sensors, climate biotech, or simply how a life of questioning can bend reality, this conversation is a field guide.

If the story resonates, subscribe, share with a friend, and leave a review with the one question this episode inspired you to ask next.

Read Shuguang's powerful essay "Life Has Ups and Downs, but Always Ask Questions": https://www.researchgate.net/publication/363521718_Life_Has_Ups_and_Downs_but_Always_Ask_Questions

Send us Fan Mail

Biomanufacturing doesn’t fail for lack of clever biology; it stalls at the factory gate. We sit down with Biosphere CEO Brian Heligman to unpack how a materials scientist’s journey through batteries and perovskites led to a bold thesis for the bioeconomy: change the constraints of the bioreactor and you change everything downstream. Instead of miles of steam lines and fragile commissioning, Biosphere is betting on UV-sterilized stainless systems, modern automation, and a full-stack approach that removes cost, complexity, and fear of contamination at scale.

Brian shares the hard lessons that shaped this strategy. In batteries, volumetric energy density mattered more than academic fashion. In solar, perovskite hype obscured the real blocker—stability. Translate that to biotech and the pattern holds: milligram wins and elegant papers won’t survive a plant with 50% contamination rates and $200 million capex. We walk through why legacy steam sterilization persists, how biopharma escaped into single-use plastics, and why industrial biotech needs a third path that’s cleaner, cheaper, and durable enough for daily production.

We also get tactical. What does it take to prove sterility “100 out of 100” times? How do you stress-test reactors with spore challenges, long sterile holds, and instrumentation that actually supports root-cause analysis? Why start with ag biologics (eg biostimulants and biopesticides) where customers feel the manufacturing bottleneck most acutely? And how can a 20,000-liter demonstration line bridge the gap between pilot and revenue, unlocking offtake and real unit economics without betting the company on a greenfield?

There’s a policy and resilience angle too. With defense and industrial strategy shifting toward domestic capability in vitamins, antibiotics, and specialty inputs, better reactors are not just a cost play, they’re a strategic asset. Over time, once performance is undeniable, even conservative markets like biopharma may follow. Until then, the opportunity is clear: lower the hurdle rate, reduce plastic waste, simplify scale-up, and let product companies focus on what customers actually want.

Send us Fan Mail

Pollution isn’t an abstract headline; it’s inside our bodies today. We sit down with Dr. Jenna Hua to reveal how small, everyday choices expose us to hormone-disrupting chemicals. Jenna explains why single-chemical research fails in a world of mixed exposures and shows how metabolomics turns invisible toxins into clear, personal insights you can act on now.

We trace Jenna’s path from nutrition research and a Fulbright in China to a painful fertility journey that exposed the limits of clinical testing. That lived experience powered a new model: targeted urine testing for bisphenols, phthalates, parabens, oxybenzone, and other chemicals, paired with education that helps you ditch high-exposure products and rethink packaging, takeout, and personal care. We also go behind the scenes on what it takes to make real-world science work: building shippable kits, solving messy logistics, and funding rigorous studies through SBIR grants when traditional investors wanted a simpler story.

Then we look forward. With the Healthy Nevada Project, Jenna’s team is connecting exposure profiles to genetics to understand who detoxes quickly, who bioactivates toxic intermediates, and how reducing exposure can change clinical outcomes in fertility, weight, and metabolic health. We break down targeted vs untargeted metabolomics, and why automation, AI, and product testing are the next frontier for honest labeling and safer supply chains. If you’ve wondered whether phthalate-free really means what it says, or how to make weight-loss therapy more effective by lowering obesogens, this conversation delivers science, strategy, and a roadmap you can use.

If this resonated, share it with a friend, subscribe for more climate biotech deep dives, and leave a review to help others discover the show. Your support helps bring rigorous, human-centered science to the problems that affect us all.

To learn more, check out:
Website: www.millionmarker.com (main company site)

Million Marker Research Institute: millionmarker.org (nonprofit side with white papers on product testing)

Send us Fan Mail

Professor Pam Silver from Harvard Medical School joins us as a founding figure and legend in synthetic biology whose scientific path led from pioneering work on nuclear localization to co-developing the revolutionary "bionic leaf"—a system that combines artificial catalysts with bacteria to convert sunlight and CO2 into fuels and compounds at efficiencies far exceeding natural photosynthesis.

Silver's perspective on synthetic biology's evolution from theoretical explorations to real-world applications is illuminating. "The only way we're going to solve the problems of the world with food and impending climate change is through engineering biology," she asserts. "Nature has solved many problems already, and the more we learn how nature solves them, we can implement that."

She doesn't shy away from controversial topics, proudly declaring herself "a full-on GMO believer" while acknowledging the ethical complexities of engineered deployments. Her approach exemplifies the powerful interface between human engineering and biological processes that characterizes her climate solutions work.

For aspiring biotechnologists, Silver offers wisdom distilled from decades at the forefront: "Be bold, take risks, but remain humble and respect nature." This balance of audacity and reverence captures her approach to reimagining biology as an engineering medium—one that might hold solutions to our most pressing planetary challenges.

Whether you're a scientist, entrepreneur, or simply curious about how biology might shape our climate future, this episode offers insights from someone who has helped define synthetic biology from its earliest days.

Send us Fan Mail